Pacira BioSciences (PCRX) News Today $25.30 +0.88 (+3.60%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$24.66 -0.65 (-2.55%) As of 03/27/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period What is Zacks Research's Forecast for PCRX FY2027 Earnings?March 25 at 2:39 AM | americanbankingnews.comSimplify Asset Management Inc. Buys Shares of 37,742 Pacira BioSciences, Inc. (NASDAQ:PCRX)Simplify Asset Management Inc. bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 37,742 shares of the company's stock, valued at approxMarch 24, 2025 | marketbeat.comWhat is Zacks Research's Estimate for PCRX FY2027 Earnings?Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Investment analysts at Zacks Research issued their FY2027 earnings per share estimates for Pacira BioSciences in a report issued on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will earn $2.45 per sharMarch 24, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 502,204 shares of the compaMarch 23, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. lessened its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 45.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,137 shareMarch 22, 2025 | marketbeat.comCommit To Buy Pacira BioSciences At $20, Earn 14.4% Annualized Using OptionsMarch 21, 2025 | nasdaq.comAmundi Purchases 15,431 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Amundi increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 200.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,114 shares of the company's stock after acquiring an additional 15,431 shaMarch 21, 2025 | marketbeat.comVictory Capital Management Inc. Sells 27,478 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Victory Capital Management Inc. decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 22.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 94,750 shares of the company's stock after selling 27March 18, 2025 | marketbeat.comPacira BioSciences adopts majority vote standard for director electionsMarch 16, 2025 | investing.comGreat Lakes Advisors LLC Sells 233,540 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Great Lakes Advisors LLC decreased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 49.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 236,552 shares of the company's stock after sMarch 16, 2025 | marketbeat.comWealthfront Advisers LLC Invests $1 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)Wealthfront Advisers LLC acquired a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 48,568 shares of the company's stock, valued at aMarch 16, 2025 | marketbeat.comBank of New York Mellon Corp Has $7.47 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Bank of New York Mellon Corp lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 11.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 396,399 shares of the company's stocMarch 16, 2025 | marketbeat.comPacira BioSciences: Back On An Uptrend After Positive DevelopmentsMarch 14, 2025 | seekingalpha.comPacira BioSciences Confirms Receipt of Director Nominations from DOMA PerpetualMarch 14, 2025 | globenewswire.comPacira BioSciences (NASDAQ:PCRX) Trading 4.3% Higher - What's Next?Pacira BioSciences (NASDAQ:PCRX) Trading 4.3% Higher - Time to Buy?March 14, 2025 | marketbeat.comDOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciencesMarch 14, 2025 | prnewswire.comPCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRXMarch 13, 2025 | globenewswire.comPacira BioSciences (NASDAQ:PCRX) Shares Down 5% - Should You Sell?Pacira BioSciences (NASDAQ:PCRX) Stock Price Down 5% - Here's WhyMarch 13, 2025 | marketbeat.comPacira BioSciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 14, 2025 Deadline to file Lead Plaintiff MotionMarch 13, 2025 | globenewswire.comPacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights – PCRXMarch 13, 2025 | globenewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraMarch 13, 2025 | prnewswire.comPacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRXMarch 13, 2025 | prnewswire.comClass Action Filed Against Pacira BioSciences, Inc. (PCRX) - March 14, 2025 Deadline to Join - Contact Levi & KorsinskyMarch 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRXMarch 11, 2025 | prnewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraMarch 11, 2025 | globenewswire.comLevi & Korsinsky Reminds Pacira BioSciences, Inc. ...March 10, 2025 | gurufocus.comLevi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 – PCRXMarch 10, 2025 | globenewswire.comShareholders that lost money on Pacira BioSciences, Inc. ...March 10, 2025 | gurufocus.comShareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRXMarch 10, 2025 | prnewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Rating of "Hold" by AnalystsShares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the nine brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four haveMarch 10, 2025 | marketbeat.comPCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 9, 2025 | globenewswire.comPCRX IMPORTANT DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in SecuMarch 8, 2025 | investing.comPACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXMarch 7, 2025 | prnewswire.comShareholders that lost money on Pacira BioSciences, Inc. ...March 7, 2025 | gurufocus.comShareholders that lost money on Pacira BioSciences, Inc. PCRX) should contact Levi & Korsinsky about pending Class Action - PCRXMarch 7, 2025 | globenewswire.comPCRX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in SecuritiesMarch 7, 2025 | investing.comFaruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRXMarch 7, 2025 | globenewswire.comPCRX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRXMarch 6, 2025 | globenewswire.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 6, 2025 | globenewswire.comThe Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming DeadlineMarch 6, 2025 | prnewswire.comPACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXMarch 5, 2025 | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraMarch 5, 2025 | prnewswire.comPACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXMarch 4, 2025 | globenewswire.comPCRX Deadline: PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud LawsuitMarch 4, 2025 | prnewswire.comShareholders that lost money on Pacira BioSciences, Inc. (PCRX) should contact Levi & Korsinsky about pending Class Action - PCRXMarch 4, 2025 | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRXMarch 4, 2025 | prnewswire.comPCRX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRXMarch 3, 2025 | globenewswire.comPCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 3, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraMarch 3, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRXMarch 3, 2025 | prnewswire.com Remove Ads Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Media Mentions By Week PCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCRX News Sentiment▼1.290.79▲Average Medical News Sentiment PCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCRX Articles This Week▼108▲PCRX Articles Average Week Remove Ads Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News Today Supernus Pharmaceuticals News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Johnson & Johnson News Today AbbVie News Today Merck & Co., Inc. News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCRX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PCRX Stock Free PCRX Stock Alerts